Parkinson's disease
Conditions
Interventions
placebo group:Randomly into group
Treatment group, :Randomly into group
Sponsors
Xuanwu Hospital of Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: A) Meets the diagnostic criteria of "clinically probable PD" for primary Parkinson's disease of MDS; B) Age 30-80 at diagnosis of Parkinson's disease; C) H-Y clinical grade =2; D) UPDRS H2o between 10 and 30 points (10 and 30 points); E) The course of disease does not exceed 5 years; F) Is not receiving anti-Parkinson's drugs or other treatment, or has been discontinued for more than 2 weeks (including dopamine preparations, dopamine agonists, COMT inhibitors, MAO inhibitors, antan, amantadine); G) Agree to participate in this study, sign the informed consent, abide by the relevant experimental regulations, take medication on time and come for regular review; H) Agree to be treated only with experimental drugs for the next 1.5 years, and to take anti-Parkinson's drugs as prescribed if necessary.
Exclusion criteria
Exclusion criteria: A) Patients with atypical or secondary Parkinson's disease; B) A history of psychiatric symptoms or mental illness; C) Cognitive impairment (MDSE =24); D) Participating in other drug trials within the past 3 months; E) Severe liver and renal function abnormalities (more than 3 times the normal mean); F) ongoing use of anti-Parkinson's drugs; G) Not to sign the informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MDS-UPDRS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Parkinson's Syndrome Scale of Chinese medicine;ADAS-cog;Parkinson's sleep scale;Olfactory Argentine Questionnaire;Depression Scale GDS-30;ROME?;MMSE&MoCA;Parkinson's Pain assessment Scale;Schwab-England Disability Scale; | — |
Countries
China
Contacts
Public ContactLi Jun
The First Affiliated Hospital of Anhui University of Chinese Medicine
Outcome results
None listed